Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with...
Autori principali: | Ruiz Garcia, V, Jobanputra, P, Burls, A, Cabello, J, Vela Casasempere, P, Bort-Marti, S, Kynaston-Pearson, F |
---|---|
Natura: | Journal article |
Lingua: | English |
Pubblicazione: |
2014
|
Documenti analoghi
Documenti analoghi
-
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
di: Ruiz Garcia, V, et al.
Pubblicazione: (2011) -
Certolizumab pegol in therapy for rheumatoid arthritis
di: Galina Viktorovna Lukina, et al.
Pubblicazione: (2012-06-01) -
Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
di: M Connock, et al.
Pubblicazione: (2010-10-01) -
QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
di: Vera Nikolayevna Amirdjanova, et al.
Pubblicazione: (2012-10-01) -
New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
di: Evgeniy L'vovich Nasonov, et al.
Pubblicazione: (2011-02-01)